Current Hematologic Malignancy Reports

Papers
(The H4-Index of Current Hematologic Malignancy Reports is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Targeting RUNX1 Germline Variants: Agents Under Investigation183
Monoclonal Gammopathy-Associated Neuropathy30
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations25
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations25
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions25
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications22
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities22
Management of Chronic Myeloid Leukemia in Children and Young Adults21
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease20
Value in Myeloma Care: Myth or Reality19
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications18
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer18
Allogeneic Transplant for CMML17
Transplantation and Cellular Therapy for Older Adults—The MSK Approach16
Prognostic and Predictive Models in Myelofibrosis16
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications15
Multiple Myeloma: Current Clinical Landscape and Compounding Costs15
0.10151982307434